Alto Neuroscience (ANRO) Preferred Stock Liabilities (2023)
Alto Neuroscience has reported Preferred Stock Liabilities over the past 1 years, most recently at $141.5 million for Q4 2023.
- Quarterly results put Preferred Stock Liabilities at $141.5 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $141.5 million (changed N/A YoY), and the annual figure for FY2023 was $141.5 million, changed.
- Preferred Stock Liabilities reached $141.5 million in Q4 2023 per ANRO's latest filing, up from $97.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $141.5 million in Q4 2023 and bottomed at $97.1 million in Q1 2023.